Guggenheim downgraded Point Biopharma (PNT) to Neutral from Buy after Eli Lilly (LLY) announced an agreement to acquire Point for $12.50 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PNT:
- Point Biopharma downgraded to Market Perform from Outperform at William Blair
- Point Biopharma downgraded to Hold from Buy at JonesResearch
- Point Biopharma downgraded to Hold from Buy at Jefferies
- Point Biopharma downgraded to Hold from Buy at Truist
- H.C. Wainwright sees Actinium Pharmaceuticals as prime candidate for acquisition